Wockhardt has received final approval from the US Food and Drug Administration (USFDA) to make and sell Promethazine hydrochloride injection, in the strengths of  25 mg/ml and 50 mg/ml. 

Promethazine hydrochloride is an antihistamine that relieves nasal stuffiness and inflammation and red, inflamed eyes caused by hay fever and other allergies.

It is also used to treat itching, swelling, and redness from hives and other rashes; allergic reactions to blood transfusions; and, with other medications, anaphylactic shock (severe allergic reaction).

Recently, the company received tentative approval from USFDA to make and sell Sumatriptan Succinate injection, in the strength of  6 mg/0.5 ml.

Shares of the company closed down Rs 3.75, or 2.22%, at Rs 166. The total volume of shares traded at the BSE was 16,384 (Friday).